Gastrointestinal Cancer News

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.

In this episode, Kevin C. Soares, MD, discusses his path to GI oncology, how immune therapy complements surgical interventions, and shares his thoughts on how the pandemic will impact medical practices.

The FDA approved ivosidenib tablets for adults with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma.

Worse outcomes were seen in COVID-19 negative patients who underwent elective colorectal surgery during the pandemic, according to a study published in Journal of Gastrointestinal Surgery.

Patients with cancer had lower rates of SARS-CoV-2 infection and mortality after two doses vs. one dose of COVID-19 vaccines, according to study results from Centre Léon Bérard Cancer Center published in Annals of Oncology.

More than 3 decades after receiving FDA approval, proton beam radiation therapy has failed to find a footing as a go-to treatment for many cancers in the United States.

In utero events such as maternal obesity and weight gain increased the risk for colorectal cancer development among adult offspring, according to research published in Gut.

Frequent drinking and not the amount of alcohol consumed per occasion was a more significant risk factor for incident gastrointestinal cancers, according to a study published in JAMA Network Open.

Early-onset colorectal cancer did not appear genomically distinct from average-onset disease, according to results of a retrospective, single-institution analysis published in Journal of the National Cancer Institute.

Higher intake of vitamin D correlated with a decreased risk for early-onset colorectal cancer and CRC precursors among a cohort of young women, according to research published in Gastroenterology.